Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice
OBJECTIVES: Teprotumumab is a novel monoclonal antibody treatment for thyroid eye disease that acts through IGF-1R inhibition. A subset of patients has been reported to experience varying levels of hearing change and other otologic symptoms after therapy. This study aimed to investigate auditory changes following monoclonal antibody IGF-1R inhibitor treatment in mice. METHODS: Adult CBA/CaJ mice were treated with varying doses of a chimeric IGF-1R monoclonal antibody (cIGF-1R mAb), saline, or IgG2a isotype controls (n = 10 per group) weekly for 20 weeks. Mice underwent auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing at regular intervals. Suprathreshold ABR Wave 1 amplitude growth functions were analyzed at the final timepoint, along with histological assessment of auditory hair cells and presynaptic ribbons. Bodyweight, exposure of cIGF-1R mAb, and the inhibitory effect of cIGF-1R mAb in lung tissues were also assessed. RESULTS: At 20 weeks, there was no significant increase in ABR or DPOAE threshold shift of the experimental cIGF-1R mAb groups compared with saline controls. No significant decrease in hair cell and presynaptic ribbon counts or suprathreshold ABR Wave 1 amplitude growth functions were observed amongst cIGF-1R mAb-treated subjects compared with saline controls. Inhibitory activity of cIGF-1R mAb was confirmed by the reduced bodyweight gain compared with controls and sustained IGF-1R pathway inhibition over the study period. CONCLUSION: IGF-1R inhibition in mice shows no consistent electrophysiologic or histological effect on auditory function. Further animal and clinical studies are warranted to evaluate a potential association between IGF-1R treatment and hearing loss. LEVEL OF EVIDENCE: N/A.
Authors
- Osama Tarabichi (ORCID: https://orcid.org/0000-0002-1295-8908)
- Alexander D. Claussen (ORCID: https://orcid.org/0000-0003-3056-5646)
- Kamelia Zerrouki
- Mohamed Amine Lounis (ORCID: https://orcid.org/0000-0001-7023-592X)
- Giustino Carnevale
- Marlan Rex Hansen (ORCID: https://orcid.org/0000-0002-6884-4897)
- Md Fahad Hossain
- Aditya Alluri (ORCID: https://orcid.org/0000-0003-3268-0883)
- Mateo Salazar
- David Redhage
- Christopher Ward (ORCID: https://orcid.org/0009-0002-3529-4312)
- Adam Vaske
- Bryce Hunger
- Caridad Naanep
- Chang‐Rung Chen
- Brajesh Kumar
Institutions
- University of Iowa (US)
- Amgen (United States) (US)
- Paraza Pharma (Canada) (CA)
Publication Details
- Journal
- The Laryngoscope
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1002/lary.71063
- Primary Topic
- Hearing, Cochlea, Tinnitus, Genetics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Horizon Therapeutics